Home · Health · Sep 18 archive
First mRNA Flu Shot Now Available for Those 50 and Older
Confirmed
In Short: Moderna’s mFlusiva, the first mRNA flu vaccine, is now available for people aged 50 and older.
Moderna’s mFlusiva, the first mRNA flu vaccine, is now available for people aged 50 and older. The vaccine, which uses the same technology as the Pfizer and Moderna COVID-19 shots, was approved by the FDA in August.
According to a late-stage clinical trial published in the New England Journal of Medicine, mFlusiva was found to be about 27% more effective than a standard flu shot. The trial involved more than 40,000 adults aged 50 and older across 11 countries.
Vaccine policy expert Dorit Reiss from the University of California Law San Francisco noted that Medicare is required to fully cover the cost of FDA-approved seasonal flu shots, but it remains unclear how widely Medicaid will cover the new mRNA shot this season.
Pharmacies are reporting that the new vaccine is causing confusion among some patients about eligibility and availability. People who do not want the mRNA vaccine can still opt for a traditional flu shot.
Scientists have long been interested in using mRNA technology for flu vaccines due to its potential to be made faster, making it easier to adapt to changing flu strains.
What's confirmed
- Moderna’s mFlusiva, the first mRNA flu vaccine, is now available for people aged 50 and older. The vaccine, which uses the same technology as the Pfizer and Moderna COVID-19 shots, was approved by the FDA in August.
- According to a late-stage clinical trial published in the New England Journal of Medicine, mFlusiva was found to be about 27% more effective than a standard flu shot. The trial involved more than 40,000 adults aged 50 and older across 11 countries.
- Vaccine policy expert Dorit Reiss from the University of California Law San Francisco noted that Medicare is required to fully cover the cost of FDA-approved seasonal flu shots, but it remains unclear how widely Medicaid will cover the new mRNA shot this season.
- Pharmacies are reporting that the new vaccine is causing confusion among some patients about eligibility and availability. People who do not want the mRNA vaccine can still opt for a traditional flu shot.
- Scientists have long been interested in using mRNA technology for flu vaccines due to its potential to be made faster, making it easier to adapt to changing flu strains.
What's still developing
- An ad-free edition is exclusively available for Bulwark+ members.
- So, as part of his PhD thesis at the University of Stuttgart, which is available in arXiv, Francesco Romano decided to solve that problem by using the very air molecules that cause that friction as fuel for a plasma engine to keep satellites aloft indefinitely in VLEO.
- These scoop up thin air in front of a spacecraft (or, in some cases, a missile) and channel that air into an electric engine, which then turns the molecules into plasma, which is then shot out the back of the engine producing thrust.
- At the end of this article, you will also find a large comparison of shots made by these top-of-the-crop smartphones.
- The table above lists the best camera smartphones tested by Notebookcheck in the last 12 months as well as other products that are relevant and still available.
- After multiple spy shots, teasers and plenty of talk around Ather’s new scooter, the company has finally taken the wraps off the Konarc.
- The Konarc is available in different versions, with the cheaper S range offering different battery sizes.
- Italian fighter jets scrambled from Šiauliai at 12.20 a.m. and shot down the drone in Lithuanian airspace, Lithuania’s armed forces said.